Tekmira Pharmaceuticals (TSX:TKM, StockForum), a Vancouver-based developer of ribonucleic acid interference therapeutic product candidates, announced today that the company had presented recent advances in messenger RNA (“mRNA”) delivery at the AsiaTIDES Conference in Tokyo, Japan.
According to the new release, Tekmira's CTO, Dr. Ian MacLachlan gave the presentation and this particular data package adds to the presentation given at the 1st International mRNA Health Conference in Tubingen, Germany.
Highlights from the presentation included that Tekmira's proprietary manufacturing methodology is the preferred method for mRNA delivery with the company successfully integrating third generation LNP technology in LNP containing mRNA.
Tekmira president and CEO, Dr. Mark J. Murray, commented, “We are pleased to present recent advances with Tekmira's LNP formulations tailored specifically for mRNA delivery. Our LNP technology is the most widely adopted delivery solution for therapeutics based on RNA interference triggers.”
He went on to explain, “However, in addition to RNAi, other important nucleic acid payloads, including messenger RNA, can be efficiently and effectively delivered using Tekmira's LNP.”
Then concluded, “By leveraging improvements in LNP technology garnered through Tekmira's siRNA-based product development programs, we have made substantial improvements in mRNA delivery, positioning us to enable the development of mRNA therapeutics by our partners as we have done with RNAi-based therapies.”
Tekmira was in the news recently when the company filed a shelf prospectus and registration sheet.
Shares gained 12.86% on the news to $27.03 per share.
Currently there are 19.0m outstanding shares with a market cap of $514.9 million.